Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO John Maraganore sold 49,457 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the transaction, the chief executive officer now owns 239,450 shares in the company, valued at approximately $16,761,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
ALNY stock traded down $1.19 during trading on Friday, reaching $67.54. The stock had a trading volume of 804,786 shares, compared to its average volume of 939,114. Alnylam Pharmaceuticals, Inc. has a one year low of $60.27 and a one year high of $124.21. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.12 and a current ratio of 9.33. The company has a market capitalization of $7.25 billion, a price-to-earnings ratio of -8.92 and a beta of 2.53.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The firm had revenue of $33.29 million during the quarter, compared to the consensus estimate of $21.60 million. During the same period in the prior year, the firm earned ($1.22) EPS. The company’s revenue was up 52.0% compared to the same quarter last year. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -8.48 EPS for the current fiscal year.
ALNY has been the topic of a number of analyst reports. Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Needham & Company LLC restated a “buy” rating and issued a $135.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, February 8th. Cantor Fitzgerald restated a “buy” rating and issued a $135.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, February 7th. Finally, Chardan Capital restated a “buy” rating and issued a $150.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $130.24.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Story: Bar Chart
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.